Potential Effects of Omega-3 Fatty Acid Supplements in the Prevention of Type 2 Diabetes: A Critical Appraisal of Data from Randomized Clinical Trials

2010 ◽  
Vol 3 (3) ◽  
pp. 140
Author(s):  
Yiqing Song ◽  
Ka He ◽  
◽  
Keyword(s):  
Type 2 Diabetes ◽  
Clinical Trials ◽  
Fatty Acid ◽  
Critical Appraisal ◽  
Randomized Clinical Trials ◽  
Omega 3 ◽  
Omega 3 Fatty Acid

Current level of fish and omega-3 fatty acid intakes and risk of Type 2 diabetes in China

2019 ◽  
Vol 74 ◽  
pp. 108249 ◽  
Author(s):  
Yu Zhang ◽  
Pan Zhuang ◽  
Lei Mao ◽  
Xiaoqian Chen ◽  
Jun Wang ◽  
...  
Keyword(s):  
Type 2 Diabetes ◽  
Fatty Acid ◽  
Current Level ◽  
Omega 3 ◽  
Omega 3 Fatty Acid

scholarly journals Effect of Vitamin D and Omega-3 Fatty Acid Supplementation on Kidney Function in Patients With Type 2 Diabetes

JAMA ◽  
2019 ◽  
Vol 322 (19) ◽  
pp. 1899 ◽  
Author(s):  
Ian H. de Boer ◽  
Leila R. Zelnick ◽  
John Ruzinski ◽  
Georgina Friedenberg ◽  
Julie Duszlak ◽  
...  
Keyword(s):  
Type 2 Diabetes ◽  
Vitamin D ◽  
Fatty Acid ◽  
Kidney Function ◽  
Omega 3 ◽  
Fatty Acid Supplementation ◽  
Acid Supplementation ◽  
Omega 3 Fatty Acid

scholarly journals Patient with Hypertriglyceridemia, Type 2 Diabetes, and Chronic Kidney Disease Treated with Atorvastatin and Omega-3 Fatty Acid Ethyl Esters

2012 ◽  
Vol 6 (1) ◽  
pp. 122-125 ◽  
Author(s):  
Vasilios G Athyros ◽  
Dimitri P Mikhailidis
Keyword(s):  
Type 2 Diabetes ◽  
Chronic Kidney Disease ◽  
Fatty Acid ◽  
Kidney Disease ◽  
Fatty Acid Ethyl Esters ◽  
Ethyl Esters ◽  
Omega 3 ◽  
Omega 3 Fatty Acid ◽  
Mixed Hyperlipidemia

This is a case report that describes a 67-year-old woman with mixed hyperlipidemia and diabetic nephropathy. She was initially prescribed a combination of simvastatin plus gemfibrozil by her general practitioner (GP). When referred to our cardiovascular unit, we further diagnosed the patient to have mixed hyperlipidemia and rhabdomyolysis. Because of concerns with her chronic kidney disease (CKD), we temporarily stopped all her drug treatments and started insulin treatment for her type 2 diabetes (T2D). A month later when her T2D was stabilised, we prescribed atorvastatin and an omega-3 fatty acid ethyl ester supplement to treat her hypertriglyceridemia. Within two months her blood lipids were within the recommended range. In patients with stage 3–5 CKD, it is not advisable to prescribe the fibrate gemfibrozil, particularly in combination with a statin that is metabolised predominantly in the kidneys. To minimise adverse events without compromise on efficacy, we used a combination of omega-3 fatty acid ethyl esters, which are not metabolised in the kidneys, with a statin that is minimally metabolised in the kidneys for the treatment of her hyperlipidemia.

scholarly journals Effect of omega‐3 fatty acid intake on homocysteine in African and Haitian Americans with type 2 diabetes

2013 ◽  
Vol 27 (S1) ◽  
Author(s):  
Joan A Vaccaro ◽  
Joel C Exebio ◽  
Sahar Ajabshir ◽  
Gustavo G Zarini ◽  
Fatma G Huffman
Keyword(s):  
Type 2 Diabetes ◽  
Fatty Acid ◽  
Fatty Acid Intake ◽  
Omega 3 ◽  
Omega 3 Fatty Acid ◽  
Acid Intake ◽  
Haitian Americans
Sign in / Sign up

Export Citation Format

Share Document